Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40656 | 0.85 | CA2 (0.77) | CA2TDP1TSHRCA1CA12 | |
| SCHEMBL7339165 | 0.84 | CA2 (0.50) | CA2TDP1TSHRALDH1A1KDM4E | |
| SCHEMBL1244949 | 0.83 | CA2 (0.59) | CA2TDP1TSHRCA1CA12 | |
| SCHEMBL6057959 | 0.82 | CA2 (0.72) | CA2TDP1TSHRCA1CA12 | |
| SCHEMBL2220712 | 0.82 | TRPA1 (0.56) | CA2TDP1TSHRALDH1A1TRPA1 | |
| SCHEMBL14072861 | 0.80 | CA2 (0.53) | CA2TSHRALDH1A1KDM4ETRPA1 | |
| SCHEMBL131361 | 0.78 | ALDH1A1 (0.67) | TDP1TSHRALDH1A1TRPA1CYP4F2 | |
| SCHEMBL5638 | 0.78 | CA2 (0.59) | CA2TDP1TSHRCA1CA12 | |
| SCHEMBL31337516 | 0.78 | TDP1 (0.42) | CA2TDP1TSHRCA1CA12 | |
| SCHEMBL5497046 | 0.78 | TSHR (0.46) | CA2TSHRALDH1A1TRPA1CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106957280-B | Ether-type aryl bridged piperazine derivatives and its salt, preparation method and the purposes in preparation treatment anti-tumor drug | 洛阳师范学院 | 2019-02-15 | — | — | CN | claimed |
| CN-106957280-A | Ether-type aryl bridged piperazine derivatives and its salt, preparation method and the purposes in treatment antineoplastic is prepared | 洛阳师范学院 | 2017-07-18 | — | — | CN | claimed |
| US-12497386-B2 | Estrogen receptor-modulating compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4561993-A1 | INHIBITORS OF PLASMA KALLIKREIN | Rezolute, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20240308986-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | RADIUS PHARMACEUTICALS, INC. | 2024-09-19 | — | — | US | disclosed |
| CN-118359610-A | MENIN-MLL interaction inhibitors | 生命医药有限责任公司 | 2024-07-19 | — | — | CN | disclosed |
| US-12018019-B2 | Estrogen receptor-modulating compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018019-B2 | Estrogen receptor-modulating compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018019-B2 | Estrogen receptor-modulating compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2024-04-18 | — | — | US | disclosed |
| WO-2024025907-A1 | INHIBITORS OF PLASMA KALLIKREIN | REZOLUTE, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-0472449-B1 | Substituted sulfonamides, processes for their preparation and medicines containing them | LIPHA (FR) | 1994-09-14 | — | — | EP | disclosed |
| EP-0496548-A1 | Carbacyclin analogs | PURDUE RESEARCH FOUNDATION (US) | 1992-07-29 | — | — | EP | disclosed |
| EP-0487270-A2 | HIV protease inhibitors having polyether substituents | MERCK & CO. INC. (US) | 1992-05-27 | — | — | EP | disclosed |
| EP-0472449-A2 | Substituted sulfonamides, processes for their preparation and medicines containing them | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1992-02-26 | — | — | EP | disclosed |
| US-5021414-A | Antiestrogen | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-06-04 | — | — | US | disclosed |
| US-4904661-A | ANTIESTROGENS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-02-27 | — | — | US | disclosed |
| US-4732912-A | ANTIESTROGENS, ANTITUMOR AGENTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-03-22 | — | — | US | disclosed |
| EP-0124369-B1 | PHENOL DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-06-24 | — | — | EP | disclosed |
| EP-0124369-A1 | Phenol derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308986-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | ESR2, GPER1, ESR1 | CA2 2407/4885TDP1 4428/4885TSHR 186/4885 |
| US-12018019-B2 | Estrogen receptor-modulating compounds | ESR2, GPER1, ESR1 | CA2 2407/4885TDP1 4428/4885TSHR 186/4885 |
| US-12497386-B2 | Estrogen receptor-modulating compounds | ESR2, GPER1, ESR1 | CA2 2407/4885TDP1 4428/4885TSHR 186/4885 |
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | CA2 4247/4885TDP1 3347/4885TSHR 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.